Boston Scientific downgraded to Hold from Buy by TD Cowen analyst Joshua Jennings today, with price target slashed to $46 from $56, implying 7.8% downside from $42.69 close. Barclays and Jefferies also cut targets this week as analysts reassess margin pressures and competitive ablation share losses in the medical device maker's core electrophysiology franchise.
BSX TD Cowen downgrades to Hold, cuts target 18% to $46.
Boston Scientific downgraded to Hold from Buy by TD Cowen analyst Joshua Jennings today, with price target slashed to $46 from $56, implying 7.8% downside from $42.69 close. Barclays and Jefferies also cut targets this week as analysts reassess margin pressures and competitive ablation share losses in the medical device maker's core electrophysiology franchise.
Key data as of 3 Nov 2026
BSX TD Cowen downgrades to Hold, cuts target 18% to $46.
2 Analyst updates in 30 days
BSX reports Tuesday with the sharpest insider-versus-analyst split in its recent history, three days before a print that will either validate the executive buying or confirm the sell-side's more cautious read. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BSX — free to start on ORTEX.
Sign up for free →Open BSX on ORTEX